Drug intelligence / Profile preview

IBP-1122

Development stage: Preclinical
Lead developer: Infant Bacterial Therapeutics
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics

Overview

IBP-1122 is an engineered live biotherapeutic product (LBP) being developed by Infant Bacterial Therapeutics (IBT) for the prevention of antibiotic-resistant hospital-acquired infections caused by vancomycin-resistant enterococci (VRE). The drug consists of a bacterial strain specifically engineered to eliminate VRE from the human microbiome, particularly the gastrointestinal tract, thereby reducing the risk of systemic infection and transmission. This technology was originally developed by researchers at the Medical College of Wisconsin (MCW), including Drs. Nita Salzman, Chris Kristich, and Sushma Kommineni, and IBT holds an exclusive global license for its development. IBP-1122 is currently in the early stages of development as part of IBT's pipeline of bacterial-based therapies aimed at addressing unmet needs in vulnerable populations.

Beyond the preview

Go deeper on IBP-1122.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBP-1122.

Explore the full profile